ストックスクリーナーアプリを入手
2.95
0.34%
-0.010
前日終値:
$2.96
開ける：
$3.02
24時間の取引高:
9.73M
Relative Volume:
1.91
時価総額：
$642.22M
収益：
$35.54M
当期純損益:
$-59.14M
株価収益率:
-8.1111
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-1.01%
1か月 パフォーマンス:
-15.71%
6か月 パフォーマンス:
-23.97%
1年 パフォーマンス:
+39.81%
1日の値動き範囲:
$2.89
$3.07
1週間の範囲:
$2.865
$3.13
52週間の値動き範囲:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.95 | 642.22M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 開始されました | Guggenheim | Buy |
| 2025-09-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
| 2021-11-15 | 開始されました | BTIG Research | Buy |
| 2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 開始されました | JP Morgan | Overweight |
| 2021-03-23 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-11-26 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-15 | 開始されました | Goldman | Neutral |
| 2018-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2018-06-01 | 開始されました | SunTrust | Buy |
| 2018-01-05 | 開始されました | Citigroup | Buy |
| 2017-09-08 | 開始されました | Wedbush | Outperform |
| 2017-03-27 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - Insider Monkey
CytomX Therapeutics Inc (CTMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytomX CFO Ogden sells $4,953 in company stock By Investing.com - Investing.com South Africa
CytomX CFO Ogden sells $4,953 in company stock - Investing.com
CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding - Stock Titan
10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytomX Therapeutics Inc (CTMX) Institutional Confidence - TradingKey
CytomX Therapeutics Inc (CTMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments - Yahoo Finance
Transcript : CytomX Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09 - marketscreener.com
CytomX Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
CytomX Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as Pipeline AdvancesAdjusted Earnings Analysis - newsline.com
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX gains as licensing deal with Regeneron expands - MSN
Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing - TradingView
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
CytomX expands Regeneron collaboration, receives $37M payment - Investing.com UK
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron - TipRanks
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
CytomX (NASDAQ: CTMX) adds programs, gains $37M from Regeneron - Stock Titan
CytomX Therapeutics (CTMX) Expands Collaboration with Regeneron Pharmaceuticals - GuruFocus
Why is CytomX Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Why is CytomX Therapeutics stock gaining today? - Investing.com
CytomX stock jumps on $37M Regeneron collaboration payment By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
CytomX expands Regeneron collaboration, receives $37M payment By Investing.com - Investing.com South Africa
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - The Manila Times
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
CytomX (CTMX) Q4 2025 Earnings Transcript - AOL.com
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):